Edition:
India

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

6.03USD
17 Jul 2018
Change (% chg)

$-0.03 (-0.50%)
Prev Close
$6.06
Open
$6.04
Day's High
$6.20
Day's Low
$5.80
Volume
80,278
Avg. Vol
150,476
52-wk High
$9.49
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Galectin Therapeutics Proceeds To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis
Monday, 14 May 2018 

May 14 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS PROCEEDS TO PHASE 3 DEVELOPMENT OF GR-MD-02 FOR NASH CIRRHOSIS FOLLOWING FDA MEETING.GALECTIN THERAPEUTICS INC - TARGET POPULATION OF PHASE 3 CLINICAL TRIAL WILL BE PATIENTS WITH NASH CIRRHOSIS WITHOUT ESOPHAGEAL VARICES.GALECTIN THERAPEUTICS INC - "DISAGREE WITH FDA'S DECISION NOT TO GRANT BREAKTHROUGH THERAPY DESIGNATION AT THIS TIME".GALECTIN THERAPEUTICS - FDA HAS NOT GRANTED BREAKTHROUGH DESIGNATION FOR PATIENTS WITH NASH CIRRHOSIS.  Full Article

Galectin Therapeutics Provides Business Update
Thursday, 29 Mar 2018 

March 29 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.GALECTIN THERAPEUTICS - BELIEVES HAS SUFFICIENT CASH TO FUND CURRENTLY PLANNED OPERATIONS & RESEARCH & DEVELOPMENT ACTIVITIES THROUGH AT LEAST MARCH 31, 2019.  Full Article

Galectin Therapeutics Says $10 Mln Credit Line From Richard Uihlein Sufficient To Cover Expected Expenditures Into 2019
Wednesday, 20 Dec 2017 

Dec 19 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS ANNOUNCES $10 MILLION CREDIT LINE FROM RICHARD E. UIHLEIN SUFFICIENT TO COVER EXPECTED EXPENDITURES INTO 2019.GALECTIN THERAPEUTICS INC - BORROWINGS UNDER CREDIT LINE ARE AT COMPANY'S DISCRETION THROUGH DECEMBER 31, 2018.  Full Article

Galectin Therapeutics Announces Results From Phase 2b NASH-CX Trial Of GR-MD-02
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS ANNOUNCES RESULTS FROM PHASE 2B NASH-CX TRIAL OF ITS PROPRIETARY COMPOUND GR-MD-02.GALECTIN - PHASE 2B TRIAL NASH-CX SHOWED STATISTICALLY SIGNIFICANT RESULTS IN REDUCING PRIMARY ENDPOINT MEASUREMENT OF HVPG VERSUS PLACEBO.GALECTIN - FOR MAJOR SECONDARY ENDPOINT ASSESSMENT OF LIVER BIOPSY, SAW STATISTICALLY SIGNIFICANT EFFECT OF TREATMENT TO IMPROVE HEPATOCYTE BALLOONING.GALECTIN - THERE WAS STATISTICALLY SIGNIFICANT REDUCTION IN DEVELOPMENT OF NEW ESOPHAGEAL VARICES IN PATIENTS WITHOUT VARICES AT BASELINE.GALECTIN-THERE WAS POSITIVE TREND IN TOTAL GROUP,BUT DIFFERENCE DID NOT REACH STATISTICAL SIGNIFICANCE IN REDUCING PRIMARY ENDPOINT MEASUREMENT OF HVPG​‍​.  Full Article

Galectin Therapeutics To Present Results From Phase 2B Nash-Cx Trial On December 5, 2017
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS TO PRESENT RESULTS FROM PHASE 2B NASH-CX TRIAL ON DECEMBER 5, 2017.  Full Article

Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Galectin Therapeutics Inc :Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results in treatment of advanced melanoma from a phase 1b clinical trial.  Full Article

Galectin Therapeutics posts qtrly loss per share $0.13‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Galectin Therapeutics Inc :Galectin Therapeutics Inc - Qtrly loss per share $0.13‍​.Galectin Therapeutics Inc - ‍Top line results of NASH-CX phase 2B clinical trial expected to be announced in early December 2017​.Galectin Therapeutics Inc - ‍Company is funded through february 2018, which is sufficient to report top line data of NASH-CX phase 2B clinical trial​.Galectin Therapeutics - Believes it has sufficient cash to fund currently planned operations and research, development activities through Dec. 31, 2017​.Galectin Therapeutics Inc - ‍As of September 30, 2017, company had $7.0 million of non-restricted cash and cash equivalents​.  Full Article

Galectin Therapeutics Q2 loss per share $0.14
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Galectin Therapeutics Inc :Galectin Therapeutics reports 2017 second quarter financial results and provides business update.Q2 loss per share $0.14.‍company is funded through January 2018​.Galectin Therapeutics - believes has sufficient cash to fund currently planned operations, research and development activities through December 31, 2017.Galectin Therapeutics Inc- as of June 30, 2017, co had $9.1 million of non-restricted cash and cash equivalents.  Full Article

Galectin Therapeutics reports Q2 loss per share $0.14 ‍​
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Galectin Therapeutics Inc :Q2 loss per share $0.14 ‍​.Galectin Therapeutics - at June 30, 2017, co had $9.1 million of unrestricted cash and cash equivalents available to fund future operations.Galectin therapeutics says with cash on hand at June 30, there is sufficient to fund currently planned operations through January 2018.  Full Article

Galectin Therapeutics says patent granted for reducing inflammatory response
Wednesday, 21 Jun 2017 

June 21 (Reuters) - Galectin Therapeutics Inc ::Galectin Therapeutics Inc says patent for reducing inflammatory response granted to co.Galectin Therapeutics Inc -the patent coverage extends through 2032.  Full Article

BRIEF-Galectin Therapeutics Provides Business Update

* GALECTIN THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE